Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD, discuss Long COVID's prevalence—noting that 1 in 5 Americans and 1 in 10 patients post-COVID may be affected.
Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (CME Credit)
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (COPE Credit)
View More
Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials
View More
Real Psychiatry 2025
January 17 - 18, 2025
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?
January 14th 2025The choice between debridement and implant exchange affects treatment outcomes for Candida-related prosthetic joint infections, highlighting the need for standardized guidelines and further research.
I’m Sorry, but It’s Time We Talk About Politics
January 10th 2025As politics increasingly intersects with science, infectious disease clinicians are called to take on advocacy roles. By engaging with their communities, clinicians can dispel misconceptions, highlight the importance of federal health institutions, and emphasize their role in safeguarding public health and advancing medical progress.
FDA Requires Guillain-Barré Syndrome Warning on 2 RSV Vaccines
January 9th 2025The federal agency approved safety labeling changes to the prescribing information for Abrysvo (Pfizer) and Arexvy (GSK) RSV vaccines for seniors after data from clinical trials, reports to the Vaccine Adverse Event Reporting System (VAERS), and a postmarketing study.
Long COVID Subsides in a Majority of Healthcare Workers
January 8th 2025A survey of this population showed that over a 2 and ½ year period, there was a decrease in post-acute sequelae of SARS-CoV-2 infection (PASC). However, 1% of respondents said they are still dealing with restrictions in their lives.